• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: Really Mild and Easily Manageable?

作者信息

Ikeda Satoshi, Misumi Toshihiro, Kato Terufumi, Okamoto Hiroaki, Ogura Takashi

机构信息

Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.

Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.

出版信息

Chest. 2022 Jul;162(1):e65-e66. doi: 10.1016/j.chest.2022.02.057.

DOI:10.1016/j.chest.2022.02.057
PMID:35809958
Abstract
摘要

相似文献

1
Immune Checkpoint Inhibitor-Induced Pneumonitis in Patients With Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: Really Mild and Easily Manageable?免疫检查点抑制剂诱发的非小细胞肺癌合并间质性肺疾病患者肺炎：真的轻微且易于管理吗？
Chest. 2022 Jul;162(1):e65-e66. doi: 10.1016/j.chest.2022.02.057.
2
Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.晚期非小细胞肺癌合并间质性肺疾病患者免疫检查点抑制剂治疗的临床结局：一项系统评价和荟萃分析
Chest. 2022 Jun;161(6):1675-1686. doi: 10.1016/j.chest.2021.12.656. Epub 2022 Jan 11.
3
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.免疫检查点抑制剂相关间质性肺病对非小细胞肺癌患者预后的影响。
Cancer Chemother Pharmacol. 2021 Feb;87(2):251-258. doi: 10.1007/s00280-020-04205-x. Epub 2021 Jan 4.
4
Risk of pneumonitis in non-small cell lung cancer patients with preexisting interstitial lung diseases treated with immune checkpoint inhibitors: a nationwide retrospective cohort study.免疫检查点抑制剂治疗伴预先存在的间质性肺疾病的非小细胞肺癌患者的肺炎风险：一项全国性回顾性队列研究。
Cancer Immunol Immunother. 2023 Mar;72(3):591-598. doi: 10.1007/s00262-022-03281-7. Epub 2022 Aug 22.
5
Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey.与非小细胞肺癌疗效和纳武利尤单抗相关间质性肺炎相关的因素：一项回顾性调查。
Cancer Control. 2020 Jan-Dec;27(4):1073274820977200. doi: 10.1177/1073274820977200.
6
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.免疫检查点抑制剂在特发性间质性肺炎的非小细胞肺癌患者中的安全性：一项匹配病例对照研究。
Cancer Chemother Pharmacol. 2022 Jan;89(1):21-30. doi: 10.1007/s00280-021-04362-7. Epub 2021 Oct 14.
7
Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.晚期或术后复发的非小细胞肺癌患者接受免疫检查点抑制剂治疗后免疫相关不良事件和肺炎的结果和危险因素。
Thorac Cancer. 2021 Jan;12(2):153-164. doi: 10.1111/1759-7714.13736. Epub 2020 Nov 17.
8
Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.非小细胞肺癌患者免疫检查点抑制剂相关肺炎的特征、发生率和危险因素。
Lung Cancer. 2018 Nov;125:150-156. doi: 10.1016/j.lungcan.2018.09.015. Epub 2018 Sep 18.
9
Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.帕博利珠单抗治疗晚期非小细胞肺癌后发生的类脂性肺炎。
Clin Lung Cancer. 2022 Mar;23(2):e116-e117. doi: 10.1016/j.cllc.2021.12.003. Epub 2021 Dec 10.
10
A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab.伴有间质性肺炎的肺多形性癌病例经帕博利珠单抗治疗获得成功。
Thorac Cancer. 2022 Jan;13(1):129-132. doi: 10.1111/1759-7714.14243. Epub 2021 Dec 3.

引用本文的文献

1
Feasibility and outcomes of curative-intent surgery for clinically node-positive non-small cell lung cancer with interstitial lung disease.
Surg Today. 2025 Oct 15. doi: 10.1007/s00595-025-03154-3.